365 related articles for article (PubMed ID: 31322208)
1. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.
Lang SH; Swift SL; White H; Misso K; Kleijnen J; Quek RGW
Int J Oncol; 2019 Sep; 55(3):597-616. PubMed ID: 31322208
[TBL] [Abstract][Full Text] [Related]
2. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
3. Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
Swift SL; Lang SH; White H; Misso K; Kleijnen J; Quek RG
Future Oncol; 2019 Oct; 15(28):3283-3303. PubMed ID: 31535940
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
Kimura H; Mizuno K; Shiota M; Narita S; Terada N; Fujimoto N; Ogura K; Hatano S; Iwasaki Y; Hakozaki N; Ishitoya S; Sumiyoshi T; Goto T; Kobayashi T; Nakagawa H; Kamoto T; Eto M; Habuchi T; Ogawa O; Momozawa Y; Akamatsu S
Br J Cancer; 2022 Nov; 127(9):1680-1690. PubMed ID: 35986085
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract][Full Text] [Related]
6. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer.
Rapposelli IG; Zampiga V; Cangini I; Arcangeli V; Ravegnani M; Valgiusti M; Pini S; Tamberi S; Bartolini G; Passardi A; Martinelli G; Calistri D; Frassineti GL; Falcini F; Danesi R
BMC Cancer; 2021 May; 21(1):611. PubMed ID: 34034685
[TBL] [Abstract][Full Text] [Related]
9. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
Abdi B; Basset N; Perrot E; Benderra MA; Khalil A; Oudard S; Blanchet P; Brureau L; Coulet F; Cussenot O; Cancel-Tassin G
Prostate; 2022 Sep; 82(12):1196-1201. PubMed ID: 35652560
[TBL] [Abstract][Full Text] [Related]
10. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
Shah S; Rachmat R; Enyioma S; Ghose A; Revythis A; Boussios S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884434
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ; Ohsumi S; Takahashi M; Fukuma E; Jung KH; Ishida T; Dai MS; Chang CH; Dalvi T; Walker G; Bennett J; O'Shaughnessy J; Balmaña J
Breast Cancer; 2022 Jan; 29(1):92-102. PubMed ID: 34467476
[TBL] [Abstract][Full Text] [Related]
12. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
13. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288
[TBL] [Abstract][Full Text] [Related]
14. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
[TBL] [Abstract][Full Text] [Related]
15. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
16. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
Lee BH
Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
[TBL] [Abstract][Full Text] [Related]
17. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
[TBL] [Abstract][Full Text] [Related]
18. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.
Abe T; Blackford AL; Tamura K; Ford M; McCormick P; Chuidian M; Almario JA; Borges M; Lennon AM; Shin EJ; Klein AP; Hruban RH; Canto MI; Goggins M
J Clin Oncol; 2019 May; 37(13):1070-1080. PubMed ID: 30883245
[TBL] [Abstract][Full Text] [Related]
19. Germline BRCA mutation in male carriers-ripe for precision oncology?
Leão RRN; Price AJ; James Hamilton R
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):48-56. PubMed ID: 29242595
[TBL] [Abstract][Full Text] [Related]
20. How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
Sciarra A; Frisenda M; Bevilacqua G; Gentilucci A; Cattarino S; Mariotti G; Del Giudice F; Di Pierro GB; Viscuso P; Casale P; Chung BI; Autorino R; Crivellaro S; Salciccia S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
